MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN US

被引：1
|
作者：
Verma, S. [1 ]
Dharmarajan, S. [1 ]
Yang, Y. [1 ]
机构：
[1] Univ Mississippi, University, MS 38677 USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72715-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A147 / A147
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
    Valencia-Mendoza, A.
    Hernandez-Garduno, A.
    Puig, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
  • [2] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [3] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [4] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [5] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE CZECH REPUBLIC
    Klimes, J.
    Mollon, P.
    Graham, C.
    Rajnoch, J.
    Dostal, F.
    Skalicky, D.
    Jordan, P.
    Depta, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A424 - A424
  • [6] Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
    Hendrix, Nathaniel
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Loos, Anne
    Liu, Shanshan
    Kumar, Varun
    Linder, Jeffrey A.
    Pearson, Steven D.
    Veenstra, David L.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1210 - +
  • [7] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kontodimas, S.
    Kourlaba, G.
    [J]. VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [8] COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS
    Ortonne, J. P.
    Feneron, D.
    Daures, J. P.
    Ollivier, A. L.
    Thiriet, C.
    Maurel, F.
    Le Pen, C.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A617 - A617
  • [9] COST-EFFECTIVENESS OF USTEKINUMAB VERSUS ETANERCEPT IN SEVERE PLAQUE PSORIASIS PATIENTS: A CANADIAN PERSPECTIVE
    Brazier, N.
    Pan, F.
    Shear, N.
    Jivraj, F.
    Schenkel, B.
    Brown, R.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [10] COST-EFFECTIVENESS OF USTEKINUMAB VS ETANERCEPT FOR SEVERE PSORIASIS
    Sura, M.
    Avxentyeva, M.
    Omelyanovsky, V
    Zorin, N.
    Hailov, P.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A506 - A506
12345